GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Net Cash per Share

Sinco Pharmaceutical Holdings (HKSE:06833) Net Cash per Share : HK$-0.44 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Sinco Pharmaceutical Holdings's Net Cash per Share for the quarter that ended in Dec. 2023 was HK$-0.44.

The historical rank and industry rank for Sinco Pharmaceutical Holdings's Net Cash per Share or its related term are showing as below:

HKSE:06833's Price-to-Net-Cash is not ranked *
in the Medical Distribution industry.
Industry Median: 9.08
* Ranked among companies with meaningful Price-to-Net-Cash only.

Sinco Pharmaceutical Holdings Net Cash per Share Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Net Cash per Share Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.37 -0.66 -0.35 -0.27 -0.44

Sinco Pharmaceutical Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.35 -0.32 -0.27 -0.28 -0.44

Competitive Comparison of Sinco Pharmaceutical Holdings's Net Cash per Share

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinco Pharmaceutical Holdings's Price-to-Net-Cash Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's Price-to-Net-Cash falls into.



Sinco Pharmaceutical Holdings Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Sinco Pharmaceutical Holdings's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(478.99-1381.034-0)/2032.89
=-0.44

Sinco Pharmaceutical Holdings's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(478.99-1381.034-0)/2032.89
=-0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinco Pharmaceutical Holdings  (HKSE:06833) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Sinco Pharmaceutical Holdings Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Traded in Other Exchanges
N/A
Address
No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.
Executives
Huang Zhijian 2305 Beneficiary of a trust
Fullwealth Holdings Limited 2201 Interest of corporation controlled by you
Risun Investments Limited 2101 Beneficial owner
Wickhams Cay Trust Company Limited 2301 Trustee
Huang Xiangbin 2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines